FBR & Co started coverage on shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) in a report published on Thursday morning. The brokerage issued an underperform rating on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on ALXN. Leerink Swann reaffirmed a buy rating on shares of Alexion Pharmaceuticals in a research note on Friday, June 17th. Piper Jaffray Cos. reaffirmed an overweight rating and set a $185.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 16th. Jefferies Group reaffirmed a hold rating on shares of Alexion Pharmaceuticals in a research note on Sunday, May 29th. Oppenheimer Holdings Inc. reaffirmed a buy rating and set a $221.00 price target (down previously from $228.00) on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. Finally, SunTrust Banks Inc. cut their price target on Alexion Pharmaceuticals from $220.00 to $197.00 and set a buy rating for the company in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $182.85.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 131.73 on Thursday. The firm has a market cap of $29.54 billion, a PE ratio of 330.98 and a beta of 1.08. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45. The stock’s 50 day moving average is $131.25 and its 200 day moving average is $135.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by $0.04. The firm had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm earned $1.44 EPS. On average, analysts anticipate that Alexion Pharmaceuticals will post $4.65 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, CFO Vikas Sinha sold 277 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $37,987.78. Following the transaction, the chief financial officer now directly owns 178,463 shares of the company’s stock, valued at approximately $24,474,415.82. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Carsten Thiel sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $125.94, for a total value of $125,940.00. Following the completion of the transaction, the executive vice president now directly owns 40,579 shares in the company, valued at $5,110,519.26. The disclosure for this sale can be found here. 4.41% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the stock. Investors Capital Advisory Services raised its position in shares of Alexion Pharmaceuticals by 0.7% in the second quarter. Investors Capital Advisory Services now owns 1,996 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 14 shares during the last quarter. Navellier & Associates Inc raised its position in shares of Alexion Pharmaceuticals by 0.5% in the second quarter. Navellier & Associates Inc now owns 3,477 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 17 shares during the last quarter. Raymond James Trust N.A. raised its position in shares of Alexion Pharmaceuticals by 0.9% in the first quarter. Raymond James Trust N.A. now owns 3,625 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 32 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its position in shares of Alexion Pharmaceuticals by 0.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 5,691 shares of the biopharmaceutical company’s stock worth $598,000 after buying an additional 43 shares during the last quarter. Finally, Rathbone Brothers plc raised its position in shares of Alexion Pharmaceuticals by 2.7% in the second quarter. Rathbone Brothers plc now owns 1,890 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 50 shares during the last quarter. 96.34% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.